CAYMAN CHEMICAL COMPANY Non-Antibody Products — page 191 of 859
Non-Antibody Products
Page 191 of 859
| Name | Description | Size | Catalog # | |
|---|---|---|---|---|
| CPI-203 | A primary amide analog of (+)-JQ1 which has shown superior bioavailability… | 1 mg | 15479-1 | More Info |
| CPI-203 | A primary amide analog of (+)-JQ1 which has shown superior bioavailability… | 10 mg | 15479-10 | More Info |
| CPI-203 | A primary amide analog of (+)-JQ1 which has shown superior bioavailability… | 25 mg | 15479-25 | More Info |
| CPI-203 | A primary amide analog of (+)-JQ1 which has shown superior bioavailability… | 5 mg | 15479-5 | More Info |
| CPI-268456 | A ligand of BRD4; binds to BRD4 (IC50 = 50 = <0.5 µM) | 1 mg | 20973-1 | More Info |
| CPI-268456 | A ligand of BRD4; binds to BRD4 (IC50 = 50 = <0.5 µM) | 10 mg | 20973-10 | More Info |
| CPI-268456 | A ligand of BRD4; binds to BRD4 (IC50 = 50 = <0.5 µM) | 25 mg | 20973-25 | More Info |
| CPI-268456 | A ligand of BRD4; binds to BRD4 (IC50 = 50 = <0.5 µM) | 5 mg | 20973-5 | More Info |
| CPI-360 | A selective EZH2 inhibitor (IC50s = 0.5 and 2.5 nM for wild-type EZH2 and… | 1 mg | 19125-1 | More Info |
| CPI-360 | A selective EZH2 inhibitor (IC50s = 0.5 and 2.5 nM for wild-type EZH2 and… | 10 mg | 19125-10 | More Info |
| CPI-360 | A selective EZH2 inhibitor (IC50s = 0.5 and 2.5 nM for wild-type EZH2 and… | 5 mg | 19125-5 | More Info |
| CPI-360 | A selective EZH2 inhibitor (IC50s = 0.5 and 2.5 nM for wild-type EZH2 and… | 500 µg | 19125-500 | More Info |
| CPI-444 | An adenosine A2A receptor antagonist; reduces tumor area in a mouse model… | 1 mg | 25024-1 | More Info |
| CPI-444 | An adenosine A2A receptor antagonist; reduces tumor area in a mouse model… | 10 mg | 25024-10 | More Info |
| CPI-444 | An adenosine A2A receptor antagonist; reduces tumor area in a mouse model… | 25 mg | 25024-25 | More Info |
| CPI-444 | An adenosine A2A receptor antagonist; reduces tumor area in a mouse model… | 5 mg | 25024-5 | More Info |
| CPI-455 | A KDM5 inhibitor; selectively inhibits KDM5A-D (IC50s = 2-10 nM) over KDM2… | 1 mg | 22127-1 | More Info |
| CPI-455 | A KDM5 inhibitor; selectively inhibits KDM5A-D (IC50s = 2-10 nM) over KDM2… | 10 mg | 22127-10 | More Info |
| CPI-455 | A KDM5 inhibitor; selectively inhibits KDM5A-D (IC50s = 2-10 nM) over KDM2… | 25 mg | 22127-25 | More Info |
| CPI-455 | A KDM5 inhibitor; selectively inhibits KDM5A-D (IC50s = 2-10 nM) over KDM2… | 5 mg | 22127-5 | More Info |
| CPI-613 | A lipoic acid analog that inhibits α-ketoglutarate dehydrogenase, pa… | 10 mg | 16981-10 | More Info |
| CPI-613 | A lipoic acid analog that inhibits α-ketoglutarate dehydrogenase, pa… | 25 mg | 16981-25 | More Info |
| CPI-613 | A lipoic acid analog that inhibits α-ketoglutarate dehydrogenase, pa… | 5 mg | 16981-5 | More Info |
| CPI-613 | A lipoic acid analog that inhibits α-ketoglutarate dehydrogenase, pa… | 50 mg | 16981-50 | More Info |
| CPI-637 | An inhibitor of CBP / EP300 bromodomains (IC50s = 30 and 51 nM in a TR-FRE… | 1 mg | 23500-1 | More Info |
| CPI-637 | An inhibitor of CBP / EP300 bromodomains (IC50s = 30 and 51 nM in a TR-FRE… | 10 mg | 23500-10 | More Info |
| CPI-637 | An inhibitor of CBP / EP300 bromodomains (IC50s = 30 and 51 nM in a TR-FRE… | 25 mg | 23500-25 | More Info |
| CPI-637 | An inhibitor of CBP / EP300 bromodomains (IC50s = 30 and 51 nM in a TR-FRE… | 5 mg | 23500-5 | More Info |
| cPLA2 Assay Kit | Arachidonoyl thio-PC is a substrate for cPLA2 by virtue of the presence of… | 96 Well | 765021-96WELLS | More Info |
| C18 ((±)-2'-hydroxy) Ceramide (d18:1/18:0) | A bioactive lipid found in the stratum corneum layer of mammalian epidermi… | 5 mg | 22687-5 | More Info |
| C12((±)-2'-hydroxy) dihydro Ceramide (d18:0/12:0) | A 2'-hydroxylated form of C12 dihydro ceramide, | 5 mg | 24435-5 | More Info |
| C16((±)-2'-hydroxy) dihydro Ceramide (d18:0/16:0) | A 2'-hydroxylated form of C16 dihydro ceramide, | 5 mg | 24436-5 | More Info |
| C18 ((±)-2'-hydroxy) dihydro Ceramide (d18:0/18:0) | A 2'-hydroxylated form of C18 dihydro ceramide | 5 mg | 24437-5 | More Info |
| CP-392,110 (maleate) | An AMPA receptor antagonist; inhibits AMPA receptor-mediated calcium uptak… | 1 mg | 20473-1 | More Info |
| CP-392,110 (maleate) | An AMPA receptor antagonist; inhibits AMPA receptor-mediated calcium uptak… | 10 mg | 20473-10 | More Info |
| CP-392,110 (maleate) | An AMPA receptor antagonist; inhibits AMPA receptor-mediated calcium uptak… | 5 mg | 20473-5 | More Info |
| 1cP-MiPLA (solution) | An analytical reference standard categorized as a lysergamide; intended fo… | 100 µg | 39013-100 | More Info |
| 4-CPPC | A MIF-2 inhibitor (IC50 = 27 µM); selective for MIF-2 over MIF-1 (IC… | 1 mg | 30068-1 | More Info |
| 4-CPPC | A MIF-2 inhibitor (IC50 = 27 µM); selective for MIF-2 over MIF-1 (IC… | 10 mg | 30068-10 | More Info |
| 4-CPPC | A MIF-2 inhibitor (IC50 = 27 µM); selective for MIF-2 over MIF-1 (IC… | 5 mg | 30068-5 | More Info |
| 4-CPPC | A MIF-2 inhibitor (IC50 = 27 µM); selective for MIF-2 over MIF-1 (IC… | 500 µg | 30068-500 | More Info |
| 13C6-6-PPD-quinone | An internal standard for the quantification of 6-PPD-quinone by GC- or LC-… | 1 mg | 40606-1 | More Info |
| 13C6-6-PPD-quinone | An internal standard for the quantification of 6-PPD-quinone by GC- or LC-… | 5 mg | 40606-5 | More Info |
| 13C6-6-PPD-quinone | An internal standard for the quantification of 6-PPD-quinone by GC- or LC-… | 500 µg | 40606-500 | More Info |
| CPPG | An antagonist of group II and group III mGluRs; It reverses inhibition of… | 1 mg | 34362-1 | More Info |
| CPPG | An antagonist of group II and group III mGluRs; It reverses inhibition of… | 10 mg | 34362-10 | More Info |
| CPPG | An antagonist of group II and group III mGluRs; It reverses inhibition of… | 25 mg | 34362-25 | More Info |
| CPPG | An antagonist of group II and group III mGluRs; It reverses inhibition of… | 5 mg | 34362-5 | More Info |
| CPPHA | A positive allosteric modulator of the mGluR5; potentiates human and rat m… | 1 mg | 21275-1 | More Info |
| CPPHA | A positive allosteric modulator of the mGluR5; potentiates human and rat m… | 10 mg | 21275-10 | More Info |
| CPPHA | A positive allosteric modulator of the mGluR5; potentiates human and rat m… | 25 mg | 21275-25 | More Info |
| CPPHA | A positive allosteric modulator of the mGluR5; potentiates human and rat m… | 5 mg | 21275-5 | More Info |
| [cPP1-7,NPY19-23,Ala31,Aib32,Gln34] - Pancreatic Polypeptide (human) (acetate) | An agonist of NPY receptor Y5; inhibits forskolin-induced cAMP production… | 1 mg | 36718-1 | More Info |
| [cPP1-7,NPY19-23,Ala31,Aib32,Gln34] - Pancreatic Polypeptide (human) (acetate) | An agonist of NPY receptor Y5; inhibits forskolin-induced cAMP production… | 10 mg | 36718-10 | More Info |
| [cPP1-7,NPY19-23,Ala31,Aib32,Gln34] - Pancreatic Polypeptide (human) (acetate) | An agonist of NPY receptor Y5; inhibits forskolin-induced cAMP production… | 5 mg | 36718-5 | More Info |
| CP21R7 | A potent and selective inhibitor of GSK3β; used as an activator of st… | 1 mg | 20573-1 | More Info |
| CP21R7 | A potent and selective inhibitor of GSK3β; used as an activator of st… | 10 mg | 20573-10 | More Info |
| CP21R7 | A potent and selective inhibitor of GSK3β; used as an activator of st… | 25 mg | 20573-25 | More Info |
| CP21R7 | A potent and selective inhibitor of GSK3β; used as an activator of st… | 5 mg | 20573-5 | More Info |
| CPS2 | A PROTAC that drives Cdk2 degradation; selectively degrades Cdk2 (IC50 = 2… | 1 mg | 40457-1 | More Info |
| CPS2 | A PROTAC that drives Cdk2 degradation; selectively degrades Cdk2 (IC50 = 2… | 10 mg | 40457-10 | More Info |
| CPS2 | A PROTAC that drives Cdk2 degradation; selectively degrades Cdk2 (IC50 = 2… | 5 mg | 40457-5 | More Info |
| CPSI-1306 | A MIF inhibitor; decreases skin thickness and MPO activity and induces ker… | 10 mg | 29905-10 | More Info |
| CPSI-1306 | A MIF inhibitor; decreases skin thickness and MPO activity and induces ker… | 25 mg | 29905-25 | More Info |
| CPSI-1306 | A MIF inhibitor; decreases skin thickness and MPO activity and induces ker… | 5 mg | 29905-5 | More Info |
| CPSI-1306 | A MIF inhibitor; decreases skin thickness and MPO activity and induces ker… | 50 mg | 29905-50 | More Info |
| 8-CPT-Cyclic AMP (sodium salt) | A lipophilic activator of PKA and PKG (Ka = 0.05 and 0.11 µM, respec… | 10 mg | 12011-10 | More Info |
| 8-CPT-Cyclic AMP (sodium salt) | A lipophilic activator of PKA and PKG (Ka = 0.05 and 0.11 µM, respec… | 25 mg | 12011-25 | More Info |
| 8-CPT-Cyclic AMP (sodium salt) | A lipophilic activator of PKA and PKG (Ka = 0.05 and 0.11 µM, respec… | 50 mg | 12011-50 | More Info |
| CPTH6 (hydrobromide) | A thiazole derivative that inhibits the lysine acetyltransferase activity… | 1 mg | 19828-1 | More Info |
| CPTH6 (hydrobromide) | A thiazole derivative that inhibits the lysine acetyltransferase activity… | 10 mg | 19828-10 | More Info |
| CPTH6 (hydrobromide) | A thiazole derivative that inhibits the lysine acetyltransferase activity… | 5 mg | 19828-5 | More Info |
| CPTH2 (hydrochloride) | Specifically inhibits Gcn5-dependent acetylation of histone H3K14 at a con… | 10 mg | 12086-10 | More Info |
| CPTH2 (hydrochloride) | Specifically inhibits Gcn5-dependent acetylation of histone H3K14 at a con… | 5 mg | 12086-5 | More Info |
| CPYPP | An inhibitor of DOCK2 (IC50 = 22.8 µM for its GEF activity), DOCK5,… | 10 mg | 17386-10 | More Info |
CAYMAN CHEMICAL COMPANY
CAYMAN CHEMICAL COMPANY
1180 East Ellsworth Road
Ann Arbor MI 48108
P: (734) 971-3335
P: (800) 364-9897 (USA & Canada only)
F: (734) 971-3640
Customer Service: custserv@caymanchem.com
Technical Support: techserv@caymanchem.com
Sales: sales@caymanchem.com
http://www.caymanchem.com
Return to Profile